Sign up to our newsletter Subscribe
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.